{
    "clinical_study": {
        "@rank": "99300", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "Sorafenib 400 mg bid continuous dose"
        }, 
        "brief_summary": {
            "textblock": "The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of\n      sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or\n      locally advanced or metastatic medullary thyroid carcinoma (MTC)."
        }, 
        "brief_title": "Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Thyroid Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or\n             metastatic MTC (medullary thyroid carcinoma)\n\n          -  Not a candidate for surgery or radiotherapy with curative intent\n\n          -  Histologically or cytologically confirmed ATC or MTC\n\n          -  Measurable or non-measurable disease (but clinically evaluable) according to RECIST\n             1.1.\n\n          -  Age >= 20 years\n\n          -  Adequate bone marrow, liver and renal function to be conducted within 14 days prior\n             to treatment\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n\n          -  Life expectancy of at least 12 weeks\n\n        Exclusion Criteria:\n\n          -  Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma\n\n          -  Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies\n             (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth\n             factor) receptors or other targeted agents\n\n          -  Prior chemotherapy for thyroid cancer (only one regimen is allowed)\n\n          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to\n             enrollment in the study.\n\n          -  Subjects with tracheal, bronchial or esophageal infiltration with significant risk of\n             bleeding but without having received local treatment prior to enrollment in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114658", 
            "org_study_id": "17073"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "description": "Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle", 
            "intervention_name": "Sorafenib (Nexavar,BAY43-9006)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anaplastic and medullary thyroid carcinoma", 
            "Thyroid Neoplasms"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kobe", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "650-0011"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsumoto", 
                        "country": "Japan", 
                        "state": "Nagano", 
                        "zip": "390-8621"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-8603"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "135-8550"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "545-8586"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in red blood cell count", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 6 months"
            }, 
            {
                "measure": "Change in white blood cell count", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 6 months"
            }, 
            {
                "measure": "Change in alanine aminotransaminase level (ALT)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 6 months"
            }, 
            {
                "measure": "Change in aspartate aminotransferase level (AST)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 6 months"
            }, 
            {
                "measure": "Change in blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114658"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response based on RECIST 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "Baseline and every 56 days up to progressive disease,an expected average of 8 months"
            }, 
            {
                "measure": "Plasma concentration of sorafenib", 
                "safety_issue": "No", 
                "time_frame": "Cycle 2 Day 1"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}